PPT-Estimated costs of managing treatment-related adverse
Author : lindy-dunigan | Published Date : 2017-07-15
eventsof nivolumab and docetaxel in the CheckMate 017 and CheckMate 057 phase III NSCLC trials Kartik Venkatachalam Intervista a Cesare Gridelli Background
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Estimated costs of managing treatment-re..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Estimated costs of managing treatment-related adverse: Transcript
eventsof nivolumab and docetaxel in the CheckMate 017 and CheckMate 057 phase III NSCLC trials Kartik Venkatachalam Intervista a Cesare Gridelli Background Nivo a PD1 antibody received FDA approval based on superior overall survival in metastatic squamous SQ and nonsquamous NSQ NSCLC patients who have progressed on or after platinumbased doublet chemotherapy The purpose of this study was to assess the frequency and associated costs of grade 24 AEs in the CheckMate 017 SQ and CheckMate 057 NSQ phase III pivotal trials of nivo vs doc in stage IIIBIV NSCLC Methods Patientlevel data from these two trials were utilized to estimate the frequency of TRAEs requiring management in the nivo and doc arms including serious and nonserious TRAEs Minimum followup for AE reporting at database lock was 12 months Grade 34 AE costs by event were identified from Healthcare Cost and Utilization Project HCUP data in 2010 which were adjusted to reflect 2012equivalent US costs Healthcare utilization associated with grade 2 AEs was based on clinical opinion and costs were based on HCUP or other sources as appropriate Results In both trials more TRAEs were observed with doc than with nivo Table and the cost of managing TRAEs was 158 and 107 times higher in the doc arm vs the nivo arm for the CheckMate 017 and CheckMate 057 trials respectively Patients in the doc arm incurred an additional 6585 and 5422 per patient in managing AEs compared with patients in the nivo arm in the above two trials respectively The total estimated costs of managing TRAEs during these trials are presented in the Table Conclusions Large estimated differences in costs were observed in managing TRAEs favoring nivo in the CheckMate 017 and CheckMate 057 pivotal trials The reduction in costs for managing AEs with the use of nivo should be considered when assessing the value of nivo in this patient population. May 21, 2012 – Call 1 of 2. Sponsoring Offices:. National Center for Ethics in Health Care . Office of Quality, Safety and Value, Risk Management Program. Welcome. Materials from this call as well as the call from August 6, 2012 (Critical Thinking About Institutional Disclosure of Adverse Events to Patients) are available on these websites:. Rachel Phillips & Victoria Cornelius. Review. “recommended improvements in the accuracy of harm data in RCT reports and a need to standardize practices for reporting.”. Review. “found that methods used to collect adverse event data, the frequency of collection, and the selection criteria used by authors for reporting adverse events vary substantially, and these events are often inadequately reported.”. Holden Comprehensive Cancer Center. Protocol Development and Monitoring . Key definitions. Identifying, documenting and reporting Adverse Events. Investigator Responsibilities . How are research participants protected? . CAUTION TIP Keep for Your Records 1Adjusted gross income you expect in 2021 (see instructions).............. 1 2Deductions.............................. 2a If you plan to itemize deductions, en Approximately 1500 Estimated velocity -16 fps Crescent shaped levee Santa Maria River looking upstream at Guadalupe GareyBridge Flow estimated at 10,000 to 15,000 cfs Estimated velocity 15 to 2 MODULE 3 Adverse events following immunizationOverviewUnder recommended conditions all vaccines used in national immunization programmes are safe and e31ective if used correctly In practice however no The initiative primarily set out to guide clinicians, mainly . rheumatologists, but also in some countries internists and immunologists, who have to play a pivotal role in developing with the oncologists a patient-centred approach to improve the diagnosis and the management of rheumatic immune-related adverse events (irAEs).. Investigator Kick-off Meeting. January 30-31, Clearwater, Florida. Jodie Riley, MISM and Robert Silbergleit. Adverse Events. Adverse Events (AEs) are “. . . any . untoward. medical occurrence in a subject that was not previously identified which does not necessarily have a causal relationship to the study drug…” . of . Life Among Patients Who Report Adverse Events . while on . Treatment . for . Drug-Resistant . TB in Johannesburg, South Africa. . Denise Evans, . Tembeka Sineke. , Kate Schnippel, Helena . van . SOURCES OF FUNDS . Purchase Price. . $. . 30,800,000 . Cap Ex Adjustment. - . Motor Vehicle Lease Buyout. Dr. Sonalika’s Eye Clinic provide the best Glaucoma treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri Dr. Sonalika’s Eye Clinic provide the best Cataract Phaco Surgery, Cataract surgery treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri Dr. Sonalika’s Eye Clinic provide the best Phaco surgery treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri Dr. Sonalika’s Eye Clinic provide the best Conjunctivitis (Pink Eye) treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri
Download Document
Here is the link to download the presentation.
"Estimated costs of managing treatment-related adverse"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents